台湾地区帕金森病患者的医疗保健利用及费用。

IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY
Kuan-Chen Chen, Li-Jung Elizabeth Ku, Ya-Hui Hu, Yu Sun, Alexis Elbaz, Pei-Chen Lee
{"title":"台湾地区帕金森病患者的医疗保健利用及费用。","authors":"Kuan-Chen Chen, Li-Jung Elizabeth Ku, Ya-Hui Hu, Yu Sun, Alexis Elbaz, Pei-Chen Lee","doi":"10.1186/s12883-024-03988-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.</p><p><strong>Objectives: </strong>This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.</p><p><strong>Methods: </strong>Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up.</p><p><strong>Results: </strong>We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer's perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity.</p><p><strong>Conclusions: </strong>This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"3"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697947/pdf/","citationCount":"0","resultStr":"{\"title\":\"Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.\",\"authors\":\"Kuan-Chen Chen, Li-Jung Elizabeth Ku, Ya-Hui Hu, Yu Sun, Alexis Elbaz, Pei-Chen Lee\",\"doi\":\"10.1186/s12883-024-03988-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.</p><p><strong>Objectives: </strong>This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.</p><p><strong>Methods: </strong>Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up.</p><p><strong>Results: </strong>We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer's perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity.</p><p><strong>Conclusions: </strong>This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation.</p>\",\"PeriodicalId\":9170,\"journal\":{\"name\":\"BMC Neurology\",\"volume\":\"25 1\",\"pages\":\"3\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697947/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12883-024-03988-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-024-03988-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:帕金森病(PD)给老年人带来了相当大的负担。台湾帕金森病患者长期费用的研究尚未得到。目的:本研究旨在探讨台湾PD病患长达15年的医疗资源利用与医疗费用,包括药物费用。方法:从2003年至2016年的国民健康保险(NHI)研究数据库中确定突发PD患者和匹配的非PD受试者。采用广义线性模型预测2003 - 2018年PD与非PD受试者年度医疗保健利用和费用的差异。我们根据PD的严重程度、年龄、性别和随访时间进行了分层分析。结果:我们确定了50,290例PD患者和201,153例非PD患者。从付款人角度来看,PD与非PD受试者的平均总医疗费用(药费)分别为新台币631,080元(新台币222,810元)与新台币480,880元(新台币140,120元)。PD诊断后的总医疗和药物费用仍然很高,从诊断后第一年的每位患者新台币138,487元到第15年的每位患者新台币154,676元。费用的最大组成部分是门诊护理(占总医疗费用的55%)和药品总费用(占总医疗费用的35%)。与中度或轻度PD患者相比,重度PD患者的总医疗费用更高,门诊和住院费用以及药物费用随着疾病严重程度的增加而增加。结论:本研究为台湾首个综合分析PD患者长期医疗保健利用及成本的研究。PD在台湾造成了重大的经济负担,其医疗(药物)费用是非PD个体的1.31(1.59)倍,并且随着PD的严重程度,费用大幅增加。我们的研究结果可以帮助卫生政策制定者了解帕金森病患者的医疗需求和医疗费用,支持有效的政策制定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.

Background: Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.

Objectives: This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.

Methods: Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up.

Results: We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer's perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity.

Conclusions: This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Neurology
BMC Neurology 医学-临床神经学
CiteScore
4.20
自引率
0.00%
发文量
428
审稿时长
3-8 weeks
期刊介绍: BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信